RxDoctor Payments Data

Anna Damian, MD

Family Medicine · Bryan, TXNPI 1861444655

Payments from drug & device makers

$61,728in general payments, 2019–2025

Across 88 payments — averaging $701.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$61K
  • Pfizer$300
  • Novo Nordisk$231
  • Boston Scientific$123
  • Merck$43
  • Lilly USA, LLC$38
  • plus $147 from 7 others

What the payments were for

  • Food & beverage$87899%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,728 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$67,487
Medicare patients
130
Services billed
741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$43,369
TrulicityDulaglutide46$42,250
JardianceEmpagliflozin28$31,163
MounjaroTirzepatide25$25,664
EliquisApixaban17$14,277
EntrestoSacubitril/Valsartan14$12,636
DuleraMometasone/Formoterol11$3,669
Metoprolol Succinate174$3,057
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,676
Enalapril Maleate132$2,280
Humalog Kwikpen U-100Insulin Lispro15$2,235
Levothyroxine Sodium159$2,099
Humalog Mix 75-25Insulin Lispro Protamin/Lispro11$1,897
Rosuvastatin Calcium124$1,688
Simvastatin157$1,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog Mix 75-25$38$69,81182 claims
Novo NordiskOzempic$231$43,36937 claims
PfizerEliquis$300$14,27717 claims
MerckDulera$43$3,66911 claims
AbbVieSynthroid$22$1,41824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →